Company Overview and News

 
Otto Energy reports successful well results at South Marsh Island Block

2018-01-29 worldoil
LONDON -- Otto Energy Limited has advised that its OCS-G34266 #F3 well (F3) on South Marsh Island Block 71 (SM 71), was drilled to a final TD of 7,717 ft Measured Depth (MD) on Jan. 26, 2018. After logging the well with open hole triple combo logging tools on Jan. 27, 2018, operations to run 7 ⅝-in. casing to TD prior to temporary suspension for completion in the D5 Sand are underway. Hydrocarbons in five discrete intervals were measured using both Log While Drilling (LWD) gamma ray and resistivity tools and wireline Triple Combo porosity tools.
Upvote Downvote

 
Otto Energy reports drilling on South Marsh Island Block, in the Gulf of Mexico

2018-01-22 worldoil
PERTH -- Otto Energy Limited has advised that the OCS G-34266 #F-3 well (F3) on South Marsh Island Block 71 (SM 71), was drilled to a depth of 3,539 ft MD on Jan. 15, 2018, where 10 3/4-in. casing was set and cemented in place. SM 71 F3 well is currently (4 p.m. USA Central Time, Jan. 21, 2018) drilling ahead at 4,969 ft MD in 9 7/8-in. hole. It is anticipated that the well will be drilled to TD and evaluated by early February.
Upvote Downvote

 
Otto Energy spuds development well on the Gulf of Mexico's South Marsh Island lease

2018-01-11 worldoil
LONDON -- Otto Energy Limited has advised that the OCS G-34266 #F-3 well (SM 71 F3), operated on behalf of the joint venture by Byron Energy Ltd. within the South Marsh Island 71 (SM 71) lease in the Gulf of Mexico shelf, is currently, at 3 p.m. on Tues., Jan. 9, 2018, CST, drilling ahead at 668 ft MD.
Upvote Downvote

 
Otto Energy announces well completion, drilling plans

2018-01-02 worldoil
WEST PERTH -- Otto Energy Limited has advised that the OCS G-34266 #F-2 well (SM 71 F2), operated on behalf of the joint venture by Byron Energy Ltd. within the South Marsh Island 71 (SM 71) lease in the Gulf Of Mexico shelf, will be completed for near term production in the B65 sand. In addition, the joint venture has approved the drilling of the F3 development well, expected to spud next week, with the intention to provide a second take point in the D5 sand zone.
Upvote Downvote

 
Installation of SM 71 F platform complete, offshore Louisiana

2017-11-22 worldoil
WEST PERTH -- Otto Energy Ltd has advised that the operator of the South Marsh Island 71 (SM 71) oil and gas development (Byron Energy Limited) has confirmed that installation of the jacket and decks comprising the SM 71 F platform is now complete. The Tetra Hedron derrick barge has de-mobilized off location after successfully placing the jacket and decks over the SM 71 F1 well (drilled in 2016) and securing the structure with pilings.
Upvote Downvote

 
Otto Energy acquires interest in ST 235 in the Gulf of Mexico

2017-10-26 worldoil
WEST PERTH -- Otto Energy Limited has announced that Houston Energy has been awarded the South Timbalier 235 (ST 235) lease under Gulf of Mexico Central Lease Sale 249.
Upvote Downvote

 
Otto Energy's positive re-rating provides opportunity for capital raising

2017-10-22 proactiveinvestors.com.au
Otto Energy Ltd's (ASX:OEL) shares closed at $0.043 on Friday, which is close to double their valuation from two months' ago.
Upvote Downvote

 
Otto Energy enters ASX halt following Byron Energy details on Gulf of Mexico

2017-07-19 proactiveinvestors.com.au
Otto Energy Ltd (ASX:OEL) is in a joint venture with Byron Energy Ltd (ASX:BYE) for the SM 71 oil development, located in the Gulf of Mexico.
Upvote Downvote

 
Half Year Report for the Period Ending 31 Dec 2016

2017-02-20 londonstockexchange
Please see below extracts from the Company's Half Year Report for the period ended 31 December 2016, being the:
Upvote Downvote

 
Quarterly Reports and Appendix 5B

2017-01-26 londonstockexchange
The Board of Red Emperor Resources NL ("Red Emperor" or the "Company") provides the following commentary and Appendix 5B for the period ending 31 December 2016.
Upvote Downvote

 
Red Emperor Resources comments on third quarter 2016 report

2016-10-25 oilvoice
The Board of Red Emperor Resources NL provides the following commentary for the period ending 30 September 2016. Philippines (SC 55) During the quarter, all relevant documentation for the transfer of Otto Energy Limited's (ASX: OEL 'Otto') equity interest in Block SC 55 was prepared by Otto, approved by the Joint Venture and has now been submitted to the Philippines Department of Energy (DoE) for final approval.
Upvote Downvote

 
Quarterly Report and Appendix 5B

2016-10-25 londonstockexchange
The Board of Red Emperor Resources NL ("Red Emperor" or the "Company") provides the following commentary and Appendix 5B for the period ending 30 September 2016.
Upvote Downvote

 
Annual Financial Report

2016-09-29 londonstockexchange
Please see below extracts from the Company's annual report for the year ending 30 June 2016 (the "Annual Report"), being:
Upvote Downvote

 
3 Net-Nets With Differences Between The Actual And The Latest Financials In Bloomberg And FT

2016-09-18 seekingalpha
Investing in net-nets can be very profitable as long as you always check the numbers with the latest information.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...